Overview:
Microbiome therapeutics market is an emerging market with abundant opportunities in today’s world. During the forecast period 2016 – 2022 market experts suggest that number of products currently involved in clinical trials proves the amount of research and development activities carried out across the world focusing on microbiome therapeutics. Considering the structure of the microbiome market the potential is quite large. The key factors assisting the growth of this market comprise rising geriatric population, increasing incidences of lifestyle diseases, increasing demand for treatments with high efficiency and low side effects. The major factors that are expected to restrain the growth of this market are lack of broad research to aid the market pull, low awareness among the population related to the efficient usage and effect of prebiotics and probiotics, and impending government regulations on probiotics and prebiotics. The segmentation of microbiome market comprises of Type of drugs, diseases and geography.
Market experts suggest that the microbial landscape of human body has attracted more than US$ 650 Mn since 2010. In recent years, probiotics, or beneficial gut bacteria therapy, have been popular. These products possess capacity of preventing number of diseases by restoring the human microbiome to its natural state. However, the overall microbiome therapeutics market is still in its infancy; hence, cannot be used as a replacement for medication or as a treatment for the eradication of the disease. Europe was observed as the leading regional market for microbiome therapeutics followed by North America. The key factors assisting the microbiome therapeutics market in Europe are due to high acceptance and rising awareness of probiotic and prebiotic products. Asia-Pacific was observed as the most potential region in terms of population and prevalence of disease throughout the forecast period.
The global microbiome therapeutics market is segmented on the following bases:
1. Type of Drugs
a. Probiotic Drugs
b. Prebiotic Drugs
i. Fructo-Oligosaccharides
ii. Galacto-Oligosaccharides
iii. Inulin
2. Type of Diseases
a. Obesity
b. Acute Diarrhea
c. Autoimmune Disorders
d. Cancer
e. Irritable Bowel Syndrome
f. Mental Disorders
g. Metabolic Disorders
h. Other Diseases
3. Geography
a. North America
i. US
ii. Canada
b. Europe
i. UK
ii. Germany
iii. Rest of Europe
c. Asia-Pacific
i. Japan
ii. China
iii. Rest of Asia Pacific
d. Latin America
i. Brazil
ii. Mexico
iii. Rest of Latin America
e. Middle East and Africa
Key Players Identified for Microbiome Therapeutics Market Include but are Not Limited to:
C3 Jian, Enterome Bioscience, Immuron, MicroBiome Therapeutics, OpenBiome, Osel, Rebiotix, Ritter Pharmaceuticals, Second Genome, Seres Therapeutics, Synthetic Biologics and others.
This report offers:
- An overview of the global markets for microbiome therapeutics
- Market trends assessment for the period 2014-2022, with historical information for 2014 & 2015, and projections through 2022, with respective CAGRS during 2016-2022
- Qualitative assessment tools such as market drivers, challenges and opportunities
- Market competition scrutiny tools such as market share analysis, fractal map assessment, Porter’s Five Forces model
- Focus on each level of market segmentation based on product approvals, launch, and current and anticipated market dynamics
- A general overview of the industry structure
- Company profiles highlighting key information about the major players operating in the microbiome therapeutics market
